Lifemd, Inc. · NASDAQ:LFMD
Lifemd — Conversion Labs — Investor Presentation (June 2020)
20 slides from Lifemd's investor presentation, Jun 19, 2020
Slide 1: Conversion Labs
, CONVERSIONL ABS C) qT”
Slide 2: Important Cautions Regarding Forward-Looking Statements
CONVERSIONLABS OTC@B:cvLB Important Cautions Regarding Forward-Looking Statements ‘Statements in this presentation that are not descriptions of historical facts are forward-looking statements relating to future events. and as such all forward-looking statements are made pursuant to the Securities Li
Slide 3: Conversion Labs offers a growing portfolio of telemedicine, online pharmacy & wellness brands
Conversion Labs offers a growing portfolio of telemedicine, online pharmacy & wellness brands Brands combine virtual medical treatment with prescription medications and unique over-the-counter products Nationwide network of licensed telehealth physicians provide virtual medical treatment, including
Slide 4: The Telemedicine & Online Pharmacy Opportunity is Massive
CONVERSIONLABS OTC@B:cvLB The Telemedicine & Online Pharmacy Opportunity is Massive Conversion Labs has a first-mover advantage in the U.S. telehealth and online pharmacy market, and is well positioned to capitalize on this disruption. US virtual care visits to soar to over 1 billion in 2020. 7 10%
Slide 5: Uniquely Positioned to Capitalize on the Growth of Online Pharmacy and Telemedicine
CONVERSIONLABS oTCa@E:cvLB Conversion Labs is Uniquely Positioned to Capitalize on the Growth of Online Pharmacy and Telemedicine Proprietary over-the-counter healthcare brands with large existing customer base Proven ability to acquire customers on the largest social media networks and search engin
Slide 6: Major Consumer and Healthcare Trends are Driving the Growth of Telemedicine & e-Wellness
CONVERSIONLABS orcae-cvia Major Consumer and Healthcare Trends are Driving the Growth of Telemedicine & e-Wellness Healthcare Trends Consumer Trends Costs of healthcare rising due to aging population and " Convenience-focused: less willing or unable to take poor public policy off work and wait in a
Slide 7: Our End-to-End Telehealth Customer Acquisition Model & Lifecycle
Our End-to-End Telehealth Customer Acqui: 7. Follow Up Rx refills, follow up consults, upsells, OTC product offerings 6. Fulfillment Same day shipping of Rx and customer service 5. Prescription Doctor to deny, approve or prescribe Rx, based on review 1. Acquisition Patient/customer views online ad,
Slide 8: Powered by Veritas MD
Powered by Veritas MD™ Veritas MD, acquired in G1 2020, is a robust telehealth technology platform that facilitates HIPAA-compliant virtual medical treatment and the prescribing of medications in all 50 states * Built to seamlessly facilitate direct-to-consumer medical treatment and Rx + Supports sy
Slide 9: Strong Revenue Growth & Financial Performance
CONVERSIONLABS orcar:cvia Strong Revenue Growth & Financial Performance Revenue Growth 50% 80% YoY Revenue Revenue CAGR Growth in 2019 2015-2019 $36.0Me a s . $38M+ 200,000+ & Annualized Net Revenue enn g Run-Rate & Growing oe & ee $14.1M. £ $aam 3 $52M — $5.1M | Scalable Telehealth Business Model w
Slide 10: Proven Direct Response Marketing Ability
CONVERSIONLABS oTcaB-cvLa Proven Direct Response Marketing Ability Consistent Top-Line Revenue Growth Since Launch of Core Brands OTC Health & Wellness Products Q417 QB Q248 Q3I8 Q418 QI-19 219 QB19 QH19 QI20 SaaS-based Service 4 $1. $12M : | IB QBIB QHE Qld Qri9 Qs19 _QtI9 — QI-20 Acquired 51% of P
Slide 11: Our Business Units
CONVERSIONLABS — oTcaB-cvLa Our Business Units n
Slide 12: Shapiro MD
Shapiro MD Shapiro MD™ is a leading hair loss treatment line for men and women. The brand combines a patented portfolio of OTC hair loss products with virtual medical treatment for hair loss across all 50 states * Developed by distinguished dermatologists Dr. Steven Shapiro, M.D., and Dr. Michael Bo
Slide 13: Rex MD
Rex MD Rex MD™ is a digital health clinic and online pharmacy for men. Initially focused on erectile dysfunction (ED) treatment, Rex MD will soon offer virtual medical treatment for skincare, longevity, mental health, primary care, and more + Brand launched in December 2019 with virtual treatment fo
Slide 14: SOSRx
SOSRx SOSRx™ is a telehealth offering that helps individuals and families prepare for emergency medical situations. The brand’s initial focus is preventative prescription and OTC products for nuclear incidents or terrorism, bioterrorism, flu epidemics, and international travel + Innovative telehealt
Slide 15: PDF Simpli
PDF Simpli PDF Simpli is a software product that enables editing, converting, compressing, splitting, or compressing PDF files. Conversion Labs owns 51% of PDF Simpli through a strategic investment made in June 2018 + Scalable search engine marketing (SEM) driven SaaS business model + PDF market est
Slide 16: Key Takeaways
CONVERSIONLABS oTcaB-cvLa Key Takeaways Revenue Growth * Sales Acceleratin; vs $12.9M in 2019 * Our telehealth infrastructure build out in 2019, now a major growth driver in 2020 * Launched Rex MD, our first telehealth brand in Q4 2019, and SOSRx Disaster Pack in Q1 2020 * Additional telehealth prod
Slide 17: Contact Us
CONVERSIONLABS oTcaB-cvLa Contact Us =~ CONVERSIONLABS Company Contact: Investor & Media Contact: Justin Schreiber Ron Both or Grant Stude President & CEO CMA Group justin@conversionlabs.com investors@conversionlabs.com (949) 432-7566 ( CVLB conversionlabs.com
Slide 18: Appendix
CONVERSIONLABS OTC@B:cvLB Appendix
Slide 19: Stock & Operational Highlights
CONVERSIONLABS —S orcas:cvis Stock & Operational Highlights Share Structure (June 1, 2020) Corporate Highlights Shares outstanding 791,123 June 16,2020 Appointed leading heath & welines doctor, ef Tl to medical aviary board ra See eee Options* 21,020,000 May 19,2020 fees ram Ne Fully Diluted 99,947,
Slide 20: Management | Board | Advisors
= CONVERSIONL ABS Management | Board | Advisors GHEEESES Board of Directors Justin Schreiber Chairman John R. Strawn, sr Director Substantial retail, healthcare, e-commerce, M&A, desthoy cx poucaese, BED: BisREnS regulatory and capital markets experience; track record Michael Borenstein, M.D. Direct